Early clinical attempts of allogeneic bone marrow transplantation(BMT) were generaly the successful, mostly due to a lock of knowledge of histocompatibility antigen and appropriate supportive care. During 1970's these area developed rather
rapidly,
and
for almost two decades, clinical allgeneic BMT has been carried out with increasing success and has expanded quickly to incorporate HLA identical siblings, HLA nonidentical related donors and recently marrow from unrelated volunteer donors.
Allogeneic
BMT have been included in the treatment of stem cell disorders such as acute and chronic leukemia, aplastic anemia, severe combined immune deficiency, Wiskott Aldrich syndrome. Fanconi's anemia, thalassemia, and sickle cell anemia, etc.
In early 1970's there was growing interest in using patient's won(autologous) bone marrow and peripheral blood stem cells in the management of malignant diseases. Now with the improvement of supportive care and technique of crvopreservation of
stem
cells, autologous BMT and peripheral blood stem cell transplantation(PBSCT) can be done after high dose chomotherapy in patients with chemosensitive tumors such as acute leukemia, breast cancer, testicular tumor, Ewing's sarcoma, lymphoma,
neuroblastoma, ovarian cancer and small cell lung cancer, These autologous BMT ad PBSCT have advantage of lack of rejection and GVHD, no need of sibling donor, and no need of anesthesia in anesthesia in case of PBSCT, and these approach has
increased
the cure rate of malignant hematologic and solid tumors.
|